Ignite Creation Date:
2024-05-05 @ 7:11 PM
Last Modification Date:
2024-10-26 @ 9:45 AM
Study NCT ID:
NCT00620633
Status:
COMPLETED
Last Update Posted:
2021-03-02
First Post:
2008-02-11
Brief Title:
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase I Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety of giving you specialized white cells from your donor They are called WT1 sensitized T cells They have been grown in the lab and are immunized against a protein The protein is called the Wilms tumor protein or WT1 Your leukemic cells make too much of this protein We want to learn whether the WT1 sensitized T cells will attack the protein and kill the leukemia cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None